

Date of Notice: 16 September 2019

**Purchaser Medsupply International Pte Ltd**

**Voluntary Recall of (brand) (strength) due to unacceptable amounts of N-nitrosodimethylamine (NDMA)**

**Dear Sir/Madam,**

*Pharmatech Resources (FE) Pte Ltd* is issuing a voluntary Class 2 recall for **all batches of *Neoceptin R 150 Tablet*** due to the presence of N-nitrosodimethylamine (NDMA). Our records indicate that you may have inventory that is impacted by this recall.

**Summary**

**Description of problem:**

Recent testing of ranitidine for nitrosamines by HSA revealed that there is trace amounts of nitrosamine NDMA present in ***Neoceptin R 150 Tablet***. The levels of NDMA detected was above internationally acceptable levels. We are investigating the root cause of issue. As a precautionary measure, *Pharmatech Resources (FE) Pte Ltd* will be recalled from all retailers.

**Customer immediate actions are required:**

Please complete the acknowledgement form and the product recall reply forms attached. If there are no stocks of the affected product to be returned, please indicate it on the recall form.

We apologize for any inconvenience that this product removal may create and appreciate your cooperation with our request. Should you have any queries please do not hesitate to contact your *Pharmatech Resources* medical representative. We appreciate your attention to this important notice and assure you that we are working to resolve and prevent such problems from occurring in the future.

We thank you for your cooperation and your patience. If you require additional information regarding this matter, please contact the *Pharmatech Resources (FE) Pte Ltd* Josephine Lee @ 9109 4466 or [jolee@pharmatechgroupe.com](mailto:jolee@pharmatechgroupe.com).

Kind regards

  
*Josephine Lee*

Group Managing Director/ Group General Manager

**PHARMATECHResources(FE) Pte Ltd**  
*Your preferred distribution solutions provider*

## Product recall reply form

### Voluntary Recall of Neoceptin R 150 Tablet 150mg due to unacceptable amounts of N-nitrosodimethylamine (NDMA)


This letter acknowledges receipt of recall of **Neoceptin R 150 Tablet 150mg** issued by company.

I have checked our stocks and quarantined the affected product, which is subjected to recall. We have received the notification about the recall.

|                                     |  |            |                |
|-------------------------------------|--|------------|----------------|
| <input checked="" type="checkbox"/> | We have checked our current inventory. We have the affected product. |            |                |
|                                     | Qty:   | zero (0)   | (complete box) |
|                                     | Qty:   | 18 tablets | (loose unit)   |
|                                     |  |            |                |

\* Please tick as appropriate.

\* If there is no stock of the product, please place a zero (0) in the box.

|                  |   |
|------------------|---|
| Hospital/clinic: | MedSupply International Pte Ltd   |
| Address:         | 10 Pioneer Crescent, Singapore 628566   |
| Contact person:  | Jean Fong   |
| Tel:             | 9170 8053   |
| Email address:   | siewjean.fong@medsupply.com   |
| Signature:       |  |

Please email the signed completed form to the below contact by 30 Sept 2019

Attention to: Pharmatech Resources (FE) Pte Ltd  
Email: jolee@pharmatechgroupe.com